Literature DB >> 12393853

Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination.

Lilin Wang1, Dan Smith, Simona Bot, Luis Dellamary, Amy Bloom, Adrian Bot.   

Abstract

The adaptive immune response is triggered by recognition of T and B cell epitopes and is influenced by "danger" motifs that act via innate immune receptors. This study shows that motifs associated with noncoding RNA are essential features in the immune response reminiscent of viral infection, mediating rapid induction of proinflammatory chemokine expression, recruitment and activation of antigen-presenting cells, modulation of regulatory cytokines, subsequent differentiation of Th1 cells, isotype switching, and stimulation of cross-priming. The heterogeneity of RNA-associated motifs results in differential binding to cellular receptors, and specifically impacts the immune profile. Naturally occurring double-stranded RNA (dsRNA) triggered activation of dendritic cells and enhancement of specific immunity, similar to selected synthetic dsRNA motifs. Based on the ability of specific RNA motifs to block tolerance induction and effectively organize the immune defense during viral infection, we conclude that such RNA species are potent danger motifs. We also demonstrate the feasibility of using selected RNA motifs as adjuvants in the context of novel aerosol carriers for optimizing the immune response to subunit vaccines. In conclusion, RNA-associated motifs produced during viral infection bridge the early response with the late adaptive phase, regulating the activation and differentiation of antigen-specific B and T cells, in addition to a short-term impact on innate immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393853      PMCID: PMC150792          DOI: 10.1172/JCI15536

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  Danger signals: SOS to the immune system.

Authors:  S Gallucci; P Matzinger
Journal:  Curr Opin Immunol       Date:  2001-02       Impact factor: 7.486

2.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

3.  Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells.

Authors:  S A Prasad; C C Norbury; W Chen; J R Bennink; J W Yewdell
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

Review 4.  Immune recognition of foreign DNA: a cure for bioterrorism?

Authors:  D M Klinman; D Verthelyi; F Takeshita; K J Ishii
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

5.  Introduction to the series. Danger model of immunity.

Authors:  P Matzinger
Journal:  Scand J Immunol       Date:  2001 Jul-Aug       Impact factor: 3.487

6.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

Authors:  A Le Bon; G Schiavoni; G D'Agostino; I Gresser; F Belardelli; D F Tough
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

Review 7.  Type I interferon gene expression: differential expression of IFN-A genes induced by viruses and double-stranded RNA.

Authors:  J Bragança; A Civas
Journal:  Biochimie       Date:  1998 Aug-Sep       Impact factor: 4.079

8.  Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Authors:  P L Earl; W Sugiura; D C Montefiori; C C Broder; S A Lee; C Wild; J Lifson; B Moss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

10.  Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.

Authors:  M Cella; M Salio; Y Sakakibara; H Langen; I Julkunen; A Lanzavecchia
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

View more
  20 in total

1.  Nuclear factor κB2 p52 protein has a role in antiviral immunity through IκB kinase epsilon-dependent induction of Sp1 protein and interleukin 15.

Authors:  Sarah L Doyle; Kari Ann Shirey; Anne F McGettrick; Elaine F Kenny; Susan Carpenter; Brian E Caffrey; Siobhan Gargan; Susan R Quinn; Jorge H Caamaño; Paul Moynagh; Stefanie N Vogel; Luke A O'Neill
Journal:  J Biol Chem       Date:  2013-07-19       Impact factor: 5.157

Review 2.  Update on toll-like receptor ligands and allergy: implications for immunotherapy.

Authors:  Anthony A Horner
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

3.  Toll-Like Receptor-3 Mediates HIV-1-Induced Interleukin-6 Expression in the Human Brain Endothelium via TAK1 and JNK Pathways: Implications for Viral Neuropathogenesis.

Authors:  Biju Bhargavan; Georgette D Kanmogne
Journal:  Mol Neurobiol       Date:  2017-11-11       Impact factor: 5.590

4.  Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity.

Authors:  Adrian Bot; Zhiyong Qiu; Raymond Wong; Mihail Obrocea; Kent A Smith
Journal:  J Transl Med       Date:  2010-12-14       Impact factor: 5.531

5.  Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Authors:  Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 6.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05

7.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles.

Authors:  Shyh-Dar Li; Yun-Ching Chen; Michael J Hackett; Leaf Huang
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

8.  Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy.

Authors:  Grégory Verdeil; Kristi Marquardt; Charles D Surh; Linda A Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

9.  HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation.

Authors:  Angela Granelli-Piperno; Angelika Golebiowska; Christine Trumpfheller; Frederick P Siegal; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

10.  Toll-like receptor-3 mediates HIV-1 transactivation via NFκB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication.

Authors:  Biju Bhargavan; Shawna M Woollard; Georgette D Kanmogne
Journal:  Cell Signal       Date:  2015-11-11       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.